Business Wire

Takeda to Demonstrate Global Leadership in Hematology at ISTH 2019


Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress (ISTH), July 6-10, 2019 in Melbourne, Australia. Showcased in 10 oral presentations and 38 poster presentations, these data underscore Takeda’s pursuit of treatment innovation to achieve optimized and personalized patient care in hematology.

“At Takeda, we are proud of the hematology heritage Shire, Baxalta and Baxter built over 70 years and we plan on expanding on it through continued research and innovation, in pursuit of a world without bleeds,” said Dr. med. Wolfhard Erdlenbruch, Vice President Head of Global Medical Affairs Hematology, Takeda. “We look forward to presenting new data from PROPEL and important updates from our gene therapy and leading factor pipeline at ISTH 2019, showcasing our continued development and commitment in this area.”

Importance of personalized prophylaxis in haemophilia
At ISTH 2019, Takeda will unveil new data from the Phase IIIb/IV PROPEL study – a PROspective, randomized, multi-center study comparing the safety and efficacy of ADYNOVATE following PK-guided prophylaxis targeting two different Factor Eight (FVIII) trough Levels in subjects with severe hemophilia A.1 This data will build on results presented at the European Association of Haemophilia and Allied Disorders (EAHAD) 2019,2 to provide important insights into the role of personalized prophylaxis for enabling improved patient outcomes and bleed protection, in people living with hemophilia A.1

  • PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study.
    • Hemophilia Optimizing Prophylaxis, ABSTRACT #OC 42.1; Monday, 08 July 2019, 14:45-16:00, Melbourne Room 2

Advancing the Promise of Gene Therapy in Hemophilia
Takeda will also present 14 scientific updates regarding its gene therapy pipeline for both hemophilia A and B. The goal of gene therapy is to enable a hemophilia patient’s body to naturally produce a sufficient amount of the missing factor VIII or IX to alleviate bleeding episodes.3 Therefore, it may be possible to help convert a hemophilia patient’s bleeding phenotype from severe to mild or even normal in some cases.4 Takeda’s TAK-754 is our AAV FVIII gene therapy vector currently under investigation in a Phase I/II trial.

Notably, Takeda will showcase the following gene therapy data, in oral presentations:

  • Nonclinical pharmacology of TAK-748/SHP648 a novel factor IX (FIX) gene therapy vector in mice and rhesus monkeys.
    • Gene Therapy Basic 1; Oral #OC 22.1 ; Sunday, 07 July 2019, 14:45-16:00, Melbourne Room 1
  • Preexisting immunity against AAV8 and other AAV serotypes in healthy individuals and patients with hemophilia B.
    • Gene Therapy Basic 2; Oral #OC31.4; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1
  • Whole exome sequencing of patients treated with adeno-associated virus serotype 8-factor IX (AAV8-FIX) gene therapy (BAX335) reveals potential determinants of persistent transgene expression.
    • Gene Therapy Basic 2; Oral #31.1; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1
  • CTLA-4 IgGs - a powerful tool to enable re-administration in AAV8 gene therapy and to suppress anti-AAV8 T cell responses.
    • Gene Therapy Basic 2; Oral #31.2; Monday, 08 July, 2019, 10:45-12:00, Melbourne Room 1

Takeda will also present 33 other scientific data releases on the company’s recently acquired broad portfolio of treatments for bleeding disorders, in oral and poster presentations throughout ISTH. These will include:

6 Hematology Franchise Product Oral Presentations

  • FVIII:
    • Development and characterization of an ELISA combined chromogenic assay for selective measurement of human FVIII activity in animal plasma matrix.
    • Development of a formulation for oral delivery of FVIII via a robotic pill.
    • The route of FVIII endocytosis by antigen-presenting cells determines the pattern of FVIII peptide-specific T cells activation.
  • TAK-755:
    • Efficacy of recombinant ADAMTS13 (TAK755) in a humanized mouse model for sickle cell disease.
    • A new transgenic mouse model tolerant to human recombinant von Willebrand factor.
    • PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: Safety and efficacy results from the phase 3 PROPEL Study

38 Poster Presentations

    • A phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A: Clinical course and outcomes in patients with target joints.
    • A retrospective, observational study using specialty pharmacy data of rurioctocog alfa pegol in clinical practice in the United States.
    • High concentrations of polyethylene glycol (PEG) mediate vacuolation of human monocyte-derived macrophages in vitro without impairing their functionality.
    • Outcomes with an extended prophylactic treatment schedule of rurioctocog alfa pegol in a phase 3b, open-label, multicenter, CONTINUATION study in previously treated patients with severe hemophilia A.
    • Safety and immunogenicity results from a phase 3b, open-label, multicenter, CONTINUATION study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A.
  • Gene Therapy:
    • Factor VIII clotting and chromogenic activities for TAK-754 / SHP654, a clinical hemophilia A gene therapy candidate, using in vitro and in vivo assays.
    • Biological relevance of low-titer anti-AAV8 neutralizing antibodies.
    • Comparative integration site analysis of two factor IX (fix) gene therapy vectors with different vector design in mice.
    • Evaluation of gene therapy mediated factor IX activity in selected in vivo test systems.
    • Immunogenicity assessment of FVIII variants for 2nd generation gene therapy.
    • Increased immunogenicity of CpG containing Adeno-associated virus serotype 8 (AAV8) constructs might contribute to the drop of transgene expression.
    • Influence of obesity on gene therapy mediated factor IX expression in mice.
    • Modulation of the Liver Immune Microenvironment by an Adeno-Associated Virus Serotype 8 Gene Therapy Vector.
    • Nonclinical efficacy and toxicology evaluation of a human FVIII gene therapy vector (TAK-754/SHP654) in mice.
    • Prevalence of preexisting immunity to adeno-associated virus (AAV) in adults with hemophilia: interim results from an international epidemiology study.
    • AHEAD International and German Studies: Subgroup analysis of patients with moderate or severe hemophilia A receiving antihemophilic factor (recombinant) as Immune Tolerance Induction (ITI) therapy.
    • Distinct antibody signatures in patients with FVIII inhibitors undergoing Immune Tolerance Induction (ITI) therapy.
    • Interferon-gamma-inducible protein 10 levels are altered in patients with haemophilia with advanced haemophiliac arthropathy.
  • FEIBA:
    • Bispecific antibodies with light chain specificity for factor IXa and X improve thrombin generation in hemophilia A plasma.
    • FVIII knock out mice treated with bypassing agent reveal thrombogenic activity when coadministered with bispecific-FIX/FX antibody.
    • Real-world clinical management of patients with hemophila and inhibitors with aPCC: efficacy and safety data after 6 months in the “FEIBA Global Outcome Study (FEIBA GO)”.
    • Safety of activated Prothrombin Complex Concentrate (aPCC) monotherapy in patients with haemophilia and inhibitors (PwHI): A systematic review.
  • Hemophilia A/ FVIII:
    • Characterisation of a new mouse model of haemophilia A developed using CRISPR/CAS9 technology.
    • Pharmacokinetic and pharmacodynamic profiles of PSAylated and PEGylated rFVIII indicate consistent extended half-life potential in rodents and monkey.
    • Adding the patient’s voice to a hemophilia specific goal menu to facilitate Goal Attainment Scaling: a qualitative study.
    • Incidence and prevalence of diagnosed and undiagnosed hemophilia A and hemophilia B in select countries.
  • TAK-755:
    • Characterization of von Willebrand factor and ADAMTS13 in the Tim Townes mouse model of sickle cell disease.
    • Cost of Illness (COI) of congenital Thrombotic Thrombocytopenic Purpura (cTTP) in the United States.
    • Design of the first clinical study of recombinant ADAMTS13 for the acute treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
    • Dose-dependent effects of recombinant ADAMTS13 (TAK755) on recovery in a humanized mouse model of sickle cell disease.
    • Efficacy and PK/PD Relationship of Recombinant ADAMTS13 (TAK755) in a Humanized Mouse Model of Sickle Cell Disease.
    • Extension of non-clinical safety margins for recombinant ADAMTS13 (TAK755)
    • Feasibility study for subcutaneous route of administration of recombinant ADAMTS13 (TAK755).
    • Recombinant ADAMTS13 (TAK755) can override the inhibitory effect of free hemoglobin on VWF multimer cleavage in vitro.
    • Recombinant ADAMTS13 reduces the cell adhesion of blood from sickle cell disease mice under shear stress.
    • Determination of large and ultra-large multimers in recombinant human VWF (rVWF) and pharmacokinetic analyses in patients with Type 3 von Willebrand Disease (VWD).
    • Infusion requirements in on demand treatment of bleeding events in von Willebrand Disease (VWD): an indirect treatment comparison between recombinant von Willebrand factor (VWF) and plasma derived VWF concentrates.
    • Bleeding patterns in patients with von Willebrand Disease: An analysis of a US medical claims database.

About Hemophilia
Hemophilia is a challenging chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.5 Hemophilia A is more common than hemophilia B;5 hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide.6

People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.7 Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.5,8

About Takeda Hematology
Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real world experience. We have 70+ years driving innovation for patients9 and a broad portfolio of 11 products across nine hemophilia indications10. Our experience as leaders in hematology means we are well prepared to meet today’s needs as we pursue future developments in the care of bleeding disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit



Klamroth R, Windyga J, Radulescu V, et al., PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 PROPEL Study. Presented at ISTH 2019 (International Society on Thrombosis and Haemostasis (ISTH) Biennial Congress. July 6-10, 2019. Abstract #A-1052-0038-01311.


Klamroth R, Windyga J, Radulescu V, et al., Results of a phase 3, randomized, multicenter study of RURIOCTOCOG ALFA PEGOL PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe Hemophilia A (propel study). Presented at European Association of Haematology and Allied Disorders (EAHAD) February 2019. Abstract #255.


National Institutes of Health: National Heart, Lung and Blood Institute. “Gene Therapy Helps Patients With Hemophilia B.” National Heart, Lung and Blood Institute website. Last Accessed April 2019.


Nathwani AC, Tuddenham EG, Rangarajan S, et al., Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B. N Engl J Med. 2011;365(25):2357–2365. Available at: Last Accessed April 2019.


World Federation of Hemophilia. “What is hemophilia?” World Federation of Hemophilia website. Last Accessed April 2019.


World Federation of Hemophilia. Report on the Annual Global Survey 2017. World Federation of Hemophilia website. Last Accessed April 2019.


World Federation of Hemophilia. “About Bleeding Disorders: Treatment.” World Federation of Hemophilia website. Last Accessed April 2019.


National Hemophilia Foundation. “Hemophilia A”. National Hemophilia Foundation website. Last Accessed April 2019.


Shire Website. Standards of Care for Hemophilia. Website: Last Accessed April 2019.


Shire Website. Product List. Website: Last Accessed June 2019

Contact information

Media Contacts:
Japanese Media
Kazumi Kobayashi
+81 (0) 3-3278-2095

Media outside Japan
Tsuyoshi Tada
+1 (617) 551-2933

Media outside Japan
Linda Calandra
+1 (617) 301-2092

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Michael Buckley to Return to True Religion Apparel as Chief Executive Officer12.11.2019 18:30:00 CETPress release

True Religion Apparel, Inc., announced that the Board of Directors has appointed Michael Buckley as its new Chief Executive Officer, effective immediately. Mr. Buckley was previously President of True Religion Apparel from 2006 to 2010. He will be responsible for developing and implementing the future vision and roadmap for True Religion. Mr. Buckley will report to the Board of Directors of the Company. Michael Buckley is a leading retail and consumer products executive with over 30 years’ successful industry experience both domestically and internationally in growing brands and creating value. He most recently was Chief Executive Officer of Differential Brands Group (renamed Centric Brands upon the acquisition of Global Brands Group) a NASDAQ publicly traded company. Differential owned the brands Hudson Jeans, Robert Graham and Swims. Prior to Differential, from 2011-2016 he was Chief Executive Officer of Robert Graham Designs until its sale to Differential Brands Group for $180 milli

Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the Journal of the American Medical Association12.11.2019 16:08:00 CETPress release

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced the publication of results from the Phase 3 CLEAR Wisdom trial in the Journal of the American Medical Association (JAMA).1 Bempedoic acid is currently undergoing review for marketing authorisation by the European Medicines Agency (EMA) and by the United States Food and Drug Administration (FDA). CLEAR Wisdom, a Phase 3, double-blind, randomised trial, evaluated the efficacy, long-term safety and tolerability of bempedoic acid 180 mg versus placebo in 779 patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolaemia (HeFH) inadequately controlled with current lipid-modifying therapies, added on to maximally-tolerated statin therapy, which may mean no statin at all.1 The JAMA publication includes results for the primary efficacy endpoint of low-density lipoprotein cholesterol (LDL-C) lowering at 12 weeks and key secondary endpoints of safety and tolerability over 52

 Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines12.11.2019 15:57:00 CETPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that the Regional Pharmaceutical Procurement Service in Northern Ireland has accepted an offer for access to all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Northern Ireland ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will have access to ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations will have access to SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor. We will support the arrangements being put in place to ensure clinicians will be able to prescribe to el

Andersen Global Announces First Collaboration in Croatia12.11.2019 14:30:00 CETPress release

Andersen Global announced today that it signed a Collaboration Agreement with one of Croatia’s largest law firms, KALLAY & PARTNERS Ltd. The addition of the Zagreb-based firm establishes Andersen Global’s presence in the country and continues the expansion of the organization in the region. Founded in 2006, KALLAY & PARTNERS Ltd. is led by Founder and Office Managing Director Marko Kallay. Under his leadership, the firm provides both foreign and domestic clients with a broad range of legal services, including banking and finance, commercial and corporate law, dispute settlement, arbitration and mediation, labor law, and regulator relationships. “Our firm values commitment, transparency, reliability and providing clients with the best-in-class legal services, and these values align well with Andersen Global’s standards and vision,” said Marko. “This collaboration will allow us to take our client service to the next level and expand our footprint more broadly. We are excited to work clos

Report: The Delivery Economy Uncovering Misalignment In the Supply Chain12.11.2019 14:00:00 CETPress release

The rapid growth of the Delivery Economy — the pervasive sentiment in which customers expect low-cost, fast and highly transparent delivery of goods — is pressuring companies to quickly address structural supply chain challenges that make it difficult for them to meet increasing customer demands, according to a new report from project44, the global leader in advanced visibility for shippers and logistics service providers. This press release features multimedia. View the full release here: (Graphic: Business Wire) The new report from project44, “Aligning the Supply Chain In The Age Of The Delivery Economy,” is based on a blind survey of 300 supply chain professionals. It is the second in a series of reports examining the emergence and impact of the Delivery Economy. The report highlights key issues plaguing both B2B and B2C supply chains and preventing adoption of the organization-wide delivery strategies that will be critical t

Modern Governance 8.0: New Report from Stanford’s Rock Center and Diligent Institute Reveals Corporate Directors Are Less Shareholder-Centric and Success Is No Longer Defined Solely by Shareholder Returns12.11.2019 14:00:00 CETPress release

In a new report released today, Diligent Institute and the Rock Center for Corporate Governance at Stanford University found that board directors consider both shareholder and stakeholder needs when making strategic decisions – reinforcing a stakeholder movement that embraces modern governance. The report, “Stakeholders Take Center Stage: Director Views on Priorities and Society,” includes responses and interviews with nearly 200 directors of public and private corporations globally. According to the survey, a vast majority of corporate directors (89%) believe it is important or very important for their company to consider the interests of non-shareholder stakeholders – such as employees, local communities, and the general public – as they work to achieve business objectives. This press release features multimedia. View the full release here: The findings of this report echo the sentiments of the recent Business Roundtable “Stat